The BME Pre Market Environment welcomes KeyZell, Pharmamel y OpenWebinars and reaches 25 companies

The Pre Market Environemnt (EpM), the BME acceleration program for the incorporation of companies into the financial markets, welcomes three new companies: KeyZell, Pharmamel and OpenWebinars. With this additions there are a total of 25 companies making up this BME initiative. From its creation, 41 companies have been trained in the Pre Market Environment, seven of which joined the financial market, the BME Growth more specifically.

KeyZell is a biopharmaceutical and Deep-Tech company that uses cutting edge technological methods to innovate in biomedical sciences wit the aim of transforming the R+D of new medicines in an integral way and the development of artificial intelligence tools to fight cancer.

Pharmamel is a biotechnological company that was born as a spin-off of the University of Granada. The company developed and patented a new intravenous melatonine based to treat the sepsis (the first cause of death in hospitals)  from the technological transference and the investment in R+D+i. After successfully testing the new drug in two phase II clinical trials and proving its efficiency and effectiveness, the company now faces the development and finalisation of the phase III clinical trials to ultimately commercialize and license it.

OpenWebinars is a Seville based company working on online technological online formation, leader in transformation and talent recruitment in the companies. Its methodology allows them to design, execute and perfect the path that companies and professionals must follow to face with guaranties its digital transformation process.

With these new incorporations, the Pre Market Environment continues to train companies for its future incorporation to the financial markets through its formation and training programs. The call for new companies to join the environment is still open and ongoing.

This BME acceleration program is the first step in the financing staircase for the companies, that continues with BME Scaleup, the market directed to emerging companies, real state investment companies (SOCIMI) and family companies that are looking for a first contact with the markets; BME Growth, the SME Stock Market in which already 140 companies are listed, and the main market.

 

Dr Nabil Hajji

Dr Nabil Hajji

World-renowned expert in the field of oncology, recognized for establishing the mechanism underlying the resistance of classical antitumor treatments in various types of cancer, related to the epigenetic mechanism that controls apoptosis and the tumor microenvironment.

Dr Nabil Hajji

Dr Nabil Hajji

World-renowned expert in the field of oncology, recognized for establishing the mechanism underlying the resistance of classical antitumor treatments in various types of cancer, related to the epigenetic mechanism that controls apoptosis and the tumor microenvironment.

Recent news

Follow us on the networks

Subscribe to our newsletters

You will only receive notifications about new news and updates.

More news

Premios EmprendeXXI de CaixaBank

KeyZell finalist in CaixaBank’s Emprende XXI Awards

KeyZell, a company dedicated to the development of artificial intelligence technology applied to cancer, has been selected as a finalist in the EmprendeXXI Awards. These ...
Read more →

KeyZell participates as a reference in biotechnology in the new edition of MAD e-Health

KeyZell has been one of the companies invited to participate on April 28th in the Madrid Capital e-Health cluster (link). The event aims to bring ...
Read more →

KeyZell awarded with the Andalucía Excelente prize, best Biotechnology company 2022.

KeyZell received the Andalucía Excelente Award as the best Biotechnology company 2022. KeyZell, awarded for its commitment to create a new future for oncology, through ...
Read more →

Comitas e-health and Keyzell implement an AI solution for the early detection of lung and breast cancer

Comitas e-health and the Andalusian company Keyzell have formalized an alliance for the development of an innovative telemedicine solution for the early diagnosis and treatment ...
Read more →

KeyZell develops the first precision medicine system to fight breast and lung cancer

The startup has developed the first oncology precision medicine system that selects “personalized treatment for each patient.”- Seguir leyendo:https://www.libertaddigital.com/ciencia-tecnologia/salud/2022-10-14/keyzell-desarrolla-el-primer-sistema-de-medicina-de-precision-para-combatir-el-cancer-de-mama-y-pulmon-6942968/   As explained by the company ...
Read more →

Fourier Intelligence, iRhythm and KeyZell are the most internationally recognized companies for revolutionizing the health sector

Health Tech World has released a compilation of the top 50 health technology innovators of 2022 who stand out for their unique innovation, outstanding technology ...
Read more →

KeyZell has been awarded as the “Most Pioneering Biotechnology Company – Europe”

KeyZell has been awarded as the “Most Pioneering Biotechnology Company – Europe” in the seventh edition of the “International Life Sciences Awards 2022“. This event ...
Read more →

KeyZell continues to advance in the development of its Artificial Intelligence tool

The biotech startup KeyZell has officially announced the launch of its exclusive fungible token useful to receive the service of its Artificial Intelligence system for precision medicine ...
Read more →

Revealed: The Health Tech World Top 50 Innovators of 2022

Health Tech World has announced its Top 50 health tech innovators of 2022. Here are the top picks of health tech companies who stand out ...
Read more →